AI assistant
Sending…
TherapeuticsMD, Inc. — Director's Dealing 2025
Feb 21, 2025
35134_dirs_2025-02-20_13c9d68e-2137-42e7-9de0-9988cc09d643.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2025-02-18
Reporting Person: Collins Cooper C. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-18 | Common Stock | M | 8500 | — | Acquired | 60516 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-18 | Restricted Stock Units | $0 | M | 8500 | Disposed | Common Stock (8500) | Direct |
Footnotes
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024.
More from TherapeuticsMD, Inc.
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
May 12
Major Shareholding Notification
2026
Apr 7
Annual Report
2026
Apr 1
Regulatory Filings
2026
Apr 1
Regulatory Filings
2026
Mar 30
Annual Report
2026
Mar 30
Regulatory Filings
2026
Jan 20
Director's Dealing
2025
Dec 29
Regulatory Filings
2025
Dec 16